N
Nephros Inc (NEPH)
Official siteHEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ
$3.00
-0.05 (-1.64%)
Market Cap: $33.15M
Last updated: Nov 17, 2026 at 11:00 AM ET
Nephros Inc (NEPH) P/E Ratio & Valuation History
Nephros (NEPH) trades at 23.1x trailing earnings and 1.5x sales. Its P/S of 1.5x is below its 5-year median of 1.7x.
Current Multiples
Its enterprise value is 15.2x its EBITDA.
| Multiple | Value |
|---|---|
| P/E (trailing) | 23.1x |
| Forward P/E | N/A |
| Price to sales | 1.5x |
| Price to book | 2.6x |
| EV/EBITDA | 15.2x |
| PEG | N/A |
Historical Medians
Against its 10-year medians, its P/S is 46.4% below 2.8x and its P/B is 50.9% below 5.3x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 1.5x | 1.7x | 2.8x |
| P/B | 2.6x | 2.8x | 5.3x |
Valuation History
Over the 9 of the 10 year ends shown that have a P/S, its P/S ranged from 1.1x in 2024 to 115.8x in 2019.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $4.88 | 44.4x | 2.8x | 5.2x |
| 2024 | $1.47 | N/A | 1.1x | 1.8x |
| 2023 | $3.46 | N/A | 2.5x | 4.4x |
| 2022 | $1.16 | N/A | 1.2x | 2.1x |
| 2021 | $5.90 | N/A | 5.7x | 5.1x |
| 2020 | $8.58 | N/A | 8.9x | 6.2x |
| 2019 | $9.95 | N/A | 115.8x | 18.3x |
| 2018 | $5.13 | N/A | N/A | 9.6x |
| 2017 | $4.05 | N/A | 22.1x | 827.5x |
| 2016 | $3.30 | N/A | 7.7x | 27.2x |
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About NEPH
Is NEPH stock overvalued?
GNG's valuation label for NEPH is Undervalued.
What is NEPH's price to sales ratio?
Nephros has a price to sales ratio of 1.5x.
NEPH pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors